Table 1.
Assessment of spatial learning in HSVcrelac (activated) and HSVlac (control) NGFXAT mice
| Session 1, s
|
Session 2,
s
|
Session 3, s
|
|||||||
|---|---|---|---|---|---|---|---|---|---|
| Trial 1 | Trial 2 | Trial 3 | Trial 1 | Trial 2 | Trial 3 | Trial 1 | Trial 2 | Trial 3 | |
| HSV crelac (activated) | 375 | 300 | 250 | 275 | 150 | 125 | 175 | 120 | 75 |
| HSVlac (control) | 450 | 425 | 400 | 375 | 350 | 350 | 375 | 345 | 300 |
Latencies for three sessions each, including three trials, are shown. Shorter latencies were exhibited for HSVcrelac (learning) than HSVlac (learning) mice. Overall RMANOVA with HSVcrelac as a between-groups factor and component, trials and sessions as within-group factors: main effect of HSVcre/ac, F(1,27) = 9.03, P = 0.006; interaction of HSVcrelac by component, F(1,27) = 10.7, P = 0.003; interaction of trials by component by HSVcrelac, F(2,54) = 10.34, P = 0.0002. Subsequent RMANOVA for each session for the learning component, all P values for HSVcrelac or interaction of HSVcrelac by treatment, P ≤ 0.05.